Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, researchers found that using the Orbis II scalp cooling device in a single-center setting effectively prevented severe chemotherapy-induced alopecia in 73% of patients with various cancer types, though the authors recommend further studies to explore broader applicability and influencing factors.

This study found that scalp hypothermia effectively prevented chemotherapy-induced alopecia in 57.3% of breast cancer patients, with side effects such as a feeling of cold and slight headaches reported in 16% of cases.

In this study, the Orbis PAXMAN® scalp cooling system showed effectiveness and good tolerability in preventing chemotherapy-induced hair loss in breast cancer patients, particularly those receiving anthracycline-free chemotherapy, though the presence of comorbidities was linked to a higher risk of severe alopecia.

This study found that scalp cooling significantly improved hair preservation and reduced psychological distress in gynecologic cancer patients undergoing chemotherapy compared to usual care.

This review discusses the incidence, reversibility, and impact of chemotherapy-induced alopecia and concludes that scalp cooling is the most effective prevention method in most cases, though some questions remain.